Small Cap Biotechnology
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
176
Greenwich LifeSciences
GLSI
$279M
| $279M | $18.99 | 3.26% |
|
177
Pyxis Oncology
PYXS
$278M
| $278M | $3.33 | 2.35% |
|
178
Palisade Bio
PALI
$277M
| $277M | $1.59 | 6.47% |
|
179
Lyell Immunopharma
LYEL
$270M
| $270M | $11.01 | 1.94% |
|
|
SION
180
Sionna Therapeutics
SION
$269M
| $269M | $5.96 | 17% |
|
181
Cue Biopharma
CUE
$269M
| $269M | $37.05 | 2.09% |
|
182
CAMP4 Therapeutics
CAMP
$266M
| $266M | $4.24 | 5.21% |
|
183
MacroGenics
MGNX
$264M
| $264M | $4.14 | 0.24% |
|
184
Entrada Therapeutics
TRDA
$263M
| $263M | $6.75 | 2.17% |
|
185
AC Immune
ACIU
$261M
| $261M | $2.63 | 1.87% |
|
186
ProQR Therapeutics
PRQR
$258M
| $258M | $1.83 | 3.17% |
|
|
BCYC
187
Bicycle Therapeutics
BCYC
$255M
| $255M | $3.65 | 0.82% |
|
188
Sutro Biopharma
STRO
$254M
| $254M | $15.34 | 0.9% |
|
Small Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 188 small cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $250M and $2B — worth a combined $157B.
The largest by market cap are Agios Pharmaceuticals (AGIO) at $1.97B, Mesoblast (MESO) at $1.96B and Rapport Therapeutics (RAPP) at $1.94B.
Among institutional investors, First Tracks Biotherapeutics (TRAX) drew the most net new fund positions in Q2 2026: 149 funds opened new positions.
- Combined market cap: $157B across 188 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: Agios Pharmaceuticals (AGIO), $1.97B market cap.
- Most net new fund positions in Q2 2026: First Tracks Biotherapeutics (TRAX), +149 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.